Attovia Therapeutics, Inc. - Common Stock (ATTO)
15.30
+0.30 (2.00%)
NASDAQ · Last Trade: Nov 6th, 2:52 PM EST
Attovia Therapeutics Reports Sustained Itch Relief in Small Study, Plans Phase 2 Trialsmarketbeat.com
Attovia Therapeutics (NASDAQ:ATTO) reported 12-week results from a small phase 1b study of its experimental itch treatment ATTO-1310, saying a single dose produced sustained responses in patients with chronic pruritus of unknown origin and in those with high-itch atopic dermatitis.
The company plan
Via MarketBeat · November 6, 2026